Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 201
Filtrar
1.
Farm. hosp ; 45(1): 10-15, ene.-feb. 2021. tab
Artículo en Español | IBECS | ID: ibc-202355

RESUMEN

OBJETIVO: Evaluar el impacto general a nivel asistencial de una comisión de terapias biológicas, en enfermedades inflamatorias inmunomediadas, mediante los hábitos de prescripción, los estudios prebiológicos y la inmunización. MÉTODO: Se realizó un estudio cuasiexperimental sobre todos los pacientes naïve mayores de edad que iniciaron tratamiento con un medicamento biológico por enfermedad inflamatoria inmunomediada el año anterior y el año posterior a la creación de la comisión de terapias biológicas. RESULTADOS: Se incluyeron un total de 31 pacientes estudiados en 2016 y 40 pacientes estudiados en 2018. La prescripción de medicamentos inhibidores del factor de necrosis tumoral α se redujo en 2018 (80,6% versus 45,0%; p < 0,05), mientras que la prescripción de inhibidores de la interleucina 12/23 aumentó (12,9% versus 35,0%; p < 0,05). El cribaje tuberculoso fue estadísticamente diferente entre los periodos pre y postcomisión de terapias biológicas: la realización del interferon gamma release assay fue superior en 2018 (9,7% versus 80,0%, p < 0,01) y la proporción de pacientes que realizaron correctamente la quimioprofilaxis fue superior en 2018 (36,4% versus 81,8 % , p < 0,05). La proporción de pruebas solicitadas para estudio de patologías víricas, así como la administración de vacunas, fueron superiores en 2018. CONCLUSIONES: El desarrollo de una comisión específica de terapias biológicas aporta mejoras asistenciales en enfermedades inflamatorias inmunomediadas, al contribuir a un mayor conocimiento relacionado con los medicamentos y con la prevención de los efectos adversos de carácter infeccioso, por lo que sería conveniente que se impulsara el desarrollo de comisiones especializadas como la comisión de terapias biológicas


OBJECTIVE: To assess the general healthcare impact of a Biological Therapies Commitee (immune-mediated inflammatory diseases) through prescription habits, pre-biological studies and immunization. METHOD: A quasi-experimental study was conducted on all naïve patients of legal age who started treatment with a biological agent for an immune-mediated inflammatory disease the year before and the year after the creation of the Biological Therapies Committee. RESULTS: A total of 31 patients treated in 2016 and 40 patients treated in 2018 were included. Prescriptions of tumor necrosis factor alpha inhibitor drugs decreased in 2018 (from 80.6% to 45.0%, p < 0.05), while prescriptions of interleukin 12/23 inhibitors increased (from 12.9% to 35.0%, p < 0.05). Tuberculosis screening was statistically different between the two periods: the number of interferon gamma release assays performed was higher in 2018 (from 9.7% to 80.0%, p < 0.01) and the proportion of patients who successfully underwent chemoprophylaxis was higher in 2018 (from 36.4% to 81.8%, p < 0.05). The proportion of tests requested for the study of viral pathologies and the number of vaccines administered were also higher in 2018. CONCLUSIONS: The development of a specific Biological Therapies Committee allows healthcare improvements, contributing to a deeper understanding of the medications and to preventing the infection-related adverse events. It would therefore seem advisable to develop specialized committees akin to the Biological Therapies Committee in other domains


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Terapia Biológica/clasificación , Enfermedades Autoinmunes/tratamiento farmacológico , Productos Biológicos/uso terapéutico , Inflamación/tratamiento farmacológico , Comisión para la Evaluación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Servicios Farmacéuticos/organización & administración , Estudios de Casos y Controles , Prescripciones de Medicamentos/clasificación , Evaluación de Eficacia-Efectividad de Intervenciones
2.
Dan Med J ; 67(6)2020 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-32741431

RESUMEN

INTRODUCTION: Polypharmacy is associated with an increased risk of adverse health outcomes. This study aims to describe the prevalence of polypharmacy and medication use among older Danish citizens. METHODS: From national registers, we extracted medicine use in relation to age group and residential region for the entire Danish population for the first half of 2016. The most frequently redeemed medicines among older citizens (≥ 75 years) in 2016 were grouped into clinically meaningful medication classes. RESULTS: The prevalence of polypharmacy (> 5 different medicines) was 51% among citizens ≥ 75 years compared with 12% for the entire Danish population. The prevalence of polypharmacy increased with age and was 7% among citizens aged 40-49 years compared with 66% among citizens aged ≥ 90 years. There were only minor regional differences in the prevalence of polypharmacy. The most commonly redeemed medicine classes and individual medicines for older citizens were: 1) pain medication: paracetamol (50%) and tramadol (14%); 2) cardiovascular medicines: acetylsalicylic acid (26%), simvastatin (25%), metoprolol (22%), amlodipine (21%), furosemide (20%), bendroflumethiazide (17%), and losartan (14%); and 3) gastrointestinal medicines: pantoprazole (15%). CONCLUSIONS: Polypharmacy is prevalent in Denmark with no relevant regional differences. The prevalence of polypharmacy increased with age, and more than half of the population aged ≥ 75 years redeemed prescriptions for > 5 different medicines. The most redeemed medicines among older citizens were against pain and cardiovascular disease. FUNDING: none. TRIAL REGISTRATION: not relevant.


Asunto(s)
Prescripciones de Medicamentos/clasificación , Prescripciones de Medicamentos/estadística & datos numéricos , Polifarmacia , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Estudios Transversales , Dinamarca/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Prevalencia , Adulto Joven
4.
Antimicrob Resist Infect Control ; 9(1): 60, 2020 05 08.
Artículo en Inglés | MEDLINE | ID: mdl-32384939

RESUMEN

BACKGROUND: In Switzerland, oral antibiotics are dispensed in packs rather than by exact pill-count. We investigated whether available packs support compliance with recommended primary care treatment regimens for common infections in children and adults. METHODS: Hospital-based guidelines for oral community -based treatment of acute otitis media, sinusitis, tonsillopharyngitis, community-acquired pneumonia and afebrile urinary tract infection were identified in 2017 in an iterative process by contacting hospital pharmacists and infectious diseases specialists. Furthermore, newly available national guidelines published in 2019 were reviewed. Available pack sizes for recommended solid, dispersible and liquid antibiotic formulations were retrieved from the Swiss pharmaceutical register and compared with recommended regimens to determine optimal (no leftovers) and adequate (optimal +/- one dose) matches. RESULTS: A large variety of recommended regimens were identified. For adults, optimal and adequate packs were available for 25/70 (36%) and 8/70 (11%) regimens, respectively. Pack-regimen matching was better for WHO Watch (optimal: 15/24, 63%) than Access antibiotics (optimal: 7/39, 18%). For the four paediatric weight-examples and 42 regimens involving child-appropriate formulations, optimal and adequate packs were available for only 14/168 (8%) and 27/168 (16%), respectively. Matching was better for older children with higher body and for longer treatment courses > 7 days. CONCLUSIONS: Fixed antibiotic packs often do not match recommended treatment regimens, especially for children, potentially resulting in longer than necessary treatments and leftover doses in the community. As part of national stewardship, a move to an exact pill-count system, including for child-appropriate solid formulations, should be considered.


Asunto(s)
Antibacterianos/administración & dosificación , Prescripciones de Medicamentos/clasificación , Otitis Media/tratamiento farmacológico , Sinusitis/tratamiento farmacológico , Administración Oral , Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos , Niño , Infecciones Comunitarias Adquiridas , Femenino , Adhesión a Directriz , Humanos , Masculino , Modelos Teóricos , Faringitis/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Atención Primaria de Salud , Suiza , Infecciones Urinarias/tratamiento farmacológico
5.
J Am Assoc Nurse Pract ; 32(1): 24-34, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31809400

RESUMEN

Although generic oral contraceptives (OCPs) can improve adherence and reduce health care expenditures, use of generic OCPs remains low, and the factors that affect generic prescribing are not well understood. We aimed to understand the barriers and facilitators of generic OCP prescribing and potential solutions to increase generic OCP prescribing, as well as pilot an educational module to address clinician misconceptions about generic OCPs. We developed focus group scripts using the 4D model of appreciative inquiry. A total of four focus groups occurred, two at the American Association of Nurse Practitioners (AANP) national conference and two at the American College of Physicians (ACP) Internal Medicine meeting. Focus group transcripts were analyzed using a constant comparative method with no a priori hypothesis to generate emerging and reoccurring themes. Findings from these focus groups were used to develop an educational module promoting generic OCP prescribing. Participants were recruited from the AANP Network for Research and the ACP Research Panel. This study demonstrates that health system factors, workflow factors, clinician factors, and patient factors were the main barriers to and facilitators of generic OCP prescribing. Nurse practitioners were responsive to an educational module and reported increased willingness to discuss and prescribe generic OCPs after completing the module. Interventions to increase generic OCP prescribing must address clinician and patient factors within the context of workflow and larger health system factors.


Asunto(s)
Anticonceptivos Orales/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Enfermeras Practicantes/normas , Competencia Clínica/normas , Competencia Clínica/estadística & datos numéricos , Curriculum/normas , Curriculum/tendencias , Prescripciones de Medicamentos/clasificación , Grupos Focales/métodos , Humanos , Enfermeras Practicantes/estadística & datos numéricos , Investigación Cualitativa , Encuestas y Cuestionarios
6.
Pharm. pract. (Granada, Internet) ; 17(4): 0-0, oct.-dic. 2019. tab, graf
Artículo en Inglés | IBECS | ID: ibc-191961

RESUMEN

BACKGROUND: Previous attempts to develop an instrument to measure factors that influence prescribing decisions among physicians were relatively insufficient and lacked validation scale. OBJECTIVE: We present a new tool that attempts to address this shortcoming. Hence, this study aims to develop and validate a self-administrated instrument to explain factors that influence the prescribing decisions of physicians. METHODS: The questionnaire was developed based on literature and then subjected to an exhaustive assessment by a board of professionals and a pilot examination before being administered to 705 physicians. Three pre-tests were carried out to evaluate the quality of the survey items. In pre-test 1, after items are generated and the validity of their content is assessed by academics and physicians. In pre-test 2, the scale is carried out with a small sample of 20 respondents of physicians. In pre-test 3, fifty drop-off questionnaires were piloted amongst physicians to test the reliability. RESULTS: On the basis of partial least squares structural equation modelling (PLS-SEM) analyses using SmartPLS 3, the content and convergent validity of the instrument were confirmed with 44 items grouped into four categories, namely, marketing efforts, patient characteristics, pharmacist variables, and contextual factors with 13 reflective constructs. CONCLUSIONS: The study outcomes prove that the scale is more valid and reliable for measuring factors that influence the decision of the physician to prescribe the drug. The development and presentation of a scale of thirteen factors related to physicians prescribing decisions help to ensure valid findings and facilitates comparisons of studies and research settings


No disponible


Asunto(s)
Humanos , Masculino , Femenino , Probabilidad , Prescripciones de Medicamentos/clasificación , Toma de Decisiones , Pautas de la Práctica en Medicina/clasificación , Psicometría/instrumentación , Puntaje de Propensión , Práctica Profesional/tendencias , Reproducibilidad de los Resultados , Análisis de los Mínimos Cuadrados
7.
Medicine (Baltimore) ; 98(32): e16646, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31393363

RESUMEN

To examine whether the Medicare Part D program had an impact on the generic drug prescription rate among residents in long-term care facilities.We analyzed prescription data for 3 drug classes (atypical antipsychotic, proton pump inhibitor, and statin) obtained from a regional online pharmacy serving long-term care centers in Pennsylvania from January 2004 to December 2007.Difference-in-difference is used as a primary analysis method, and different regression methods (probit and multinomial) are used to accommodate different types of outcome measures.Contrary to expectations, the Part D program did not have a statistically significant impact on the generic prescription rate in the long-term care setting during the study period. Only the statin class showed a dramatic increase in generic drug prescriptions, mainly due to the loss of patent protection for one of the most popular brand-name drugs in the class.The complex dynamics of the prescription drug market, particularly the availability of generic versions of popular prescription medications, had a bigger role in increasing the prescription rate of generic drugs than the Part D program. This warrants the need to relax prescription medicines' patent policies and for further study on the impact of such policies.


Asunto(s)
Prescripciones de Medicamentos/estadística & datos numéricos , Medicamentos Genéricos , Seguro de Servicios Farmacéuticos/estadística & datos numéricos , Medicare Part D/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Antipsicóticos , Estudios de Casos y Controles , Prescripciones de Medicamentos/clasificación , Sustitución de Medicamentos , Revisión de la Utilización de Medicamentos , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Cuidados a Largo Plazo/estadística & datos numéricos , Masculino , Inhibidores de la Bomba de Protones , Estados Unidos
8.
HEC Forum ; 31(4): 295-304, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31396763

RESUMEN

This paper critically examines the implications of state efforts to expand prescriptive authority of pharmacists, which will allow them to prescribe various types of hormonal contraceptives. With this expansion, women no longer need to see a physician before being prescribed such contraceptives, but instead, they must answer self-assessment questionnaires at the pharmacy to ensure that their chosen method is safe and appropriate. This paper argues that while these measures to expand pharmacists' prescriptive authority will surely meet the stated goal to increase access to hormonal contraceptives, the measures may have detrimental consequences that have largely been downplayed. Studies consistently show that the OB-GYN is a significant primary care provider identified by young female patients, and some of the main reasons provided by these young women for going to the OB-GYN is to discuss, or obtain a prescription for, contraceptives. Through the expansion of pharmacists' prescriptive authority, a likely consequence is that some women will relinquish going to the OB-GYN. However, the OB-GYN provides important services beyond contraceptives, such as preventive screenings for hypertension, cardiovascular diseases, alcohol abuse, mental health, etc., and there is evidence supporting both the effectiveness and cost-benefits of these interventions. By increasing access to contraceptives, the likely result is that many women will have less interaction with a physician and will receive fewer preventive screenings. I do not wish to suggest that these bills should not pass, nor that OB-GYNs should hold contraceptives hostage, only that there are consequences to expanded prescriptive authority that must be anticipated. Further, expanding prescriptive authority obscures the real problem: some individuals have trouble accessing the health care system, not merely trouble accessing hormonal contraceptives. The expansion of prescriptive authority to include contraceptives applies a Band-Aid to treat one aspect of this problem. What is needed is not merely expanded access to hormonal contraceptives, but better access to health care in general.


Asunto(s)
Anticonceptivos/uso terapéutico , Prescripciones de Medicamentos/clasificación , Farmacéuticos/legislación & jurisprudencia , Anticonceptivos/administración & dosificación , Anticonceptivos Poscoito/administración & dosificación , Anticonceptivos Poscoito/uso terapéutico , Servicios de Planificación Familiar/legislación & jurisprudencia , Servicios de Planificación Familiar/métodos , Humanos , Encuestas y Cuestionarios
9.
Rev Saude Publica ; 53: 51, 2019 May 30.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-31166379

RESUMEN

OBJECTIVE: Trace the pattern of drug use during delivery hospitalization. METHOD: Cross-sectional study carried out from June to October 2015, included in the 2015 Pelotas births cohort. All women living in the urban area of the city who were hospitalized for delivery were part of the sample. We collected information regarding drug prescription and drug use by mothers during the whole period of hospitalization. Sociodemographic data were obtained in interview after delivery, and other data were obtained from medical charts. The drugs were classified according to the Anatomical Therapeutic Chemical system. RESULTS: All study participants (1,392 women) used at least one drug, with the mean amount being larger the higher the age of the mother, both prepartum/during delivery and postpartum. It was also higher in cases of spinal anesthesia or general anesthesia, cesarean deliveries, school hospitals, and longer hospitalizations. Analysis of the sample as a whole showed no significant difference in the number of drugs used according to hospitalization type, but when stratified by length of hospital stay the mean was higher in SUS hospitalizations than in private and health insurance hospitalizations. Drugs for the nervous system were the most used (30.5%), followed by drugs for the alimentary tract and metabolism (13.8%). The use of anti-infective agents and drugs that act on the cardiovascular and respiratory systems was higher in mothers who underwent cesarean delivery. This study showed high drug consumption in the delivery hospitalization period, and showed cesarean delivery and epidural anesthesia as the main factors related to high drug consumption in this period. CONCLUSIONS: We found high drug consumption in the delivery hospitalization period, and the main factors were cesarean delivery and epidural anesthesia. Drugs that act on the nervous system were the most used.


Asunto(s)
Cesárea/estadística & datos numéricos , Parto Obstétrico/estadística & datos numéricos , Prescripciones de Medicamentos/estadística & datos numéricos , Utilización de Medicamentos/estadística & datos numéricos , Adolescente , Adulto , Anestesia Epidural , Anestesia General , Anestesia Raquidea , Brasil , Estudios de Cohortes , Estudios Transversales , Prescripciones de Medicamentos/clasificación , Femenino , Hospitalización , Humanos , Persona de Mediana Edad , Periodo Posparto , Embarazo , Factores de Riesgo , Factores Socioeconómicos , Adulto Joven
10.
Gac. sanit. (Barc., Ed. impr.) ; 33(2): 112-118, mar.-abr. 2019. tab, graf
Artículo en Español | IBECS | ID: ibc-183672

RESUMEN

Objetivos: Los objetivos de este estudio son describir la frecuencia de exposición y la actitud de los médicos internos residentes (MIR) de la Comunidad de Madrid (CM) con la industria farmacéutica (IF), y analizar la asociación con la especialidad, el entorno profesional y la formación recibida. Métodos: Estudio descriptivo mediante encuesta electrónica durante mayo y junio de 2015 a los MIR de la CM. Se recogieron variables sociodemográficas y de relación con la IF en cuatro bloques: frecuencia de interacción, actitudes y percepciones, entorno y marco regulatorio, y habilidades adquiridas; con los dos primeros se elaboró un índice sintético de relación con la IF (ISIF). Análisis bivariado y multivariado de regresión logística. Resultados: Respondieron 350 residentes (28% de medicina familiar y comunitaria [MFyC]), 57% de especialidades hospitalarias y 15% de otras). El 98% refirió haber tenido relación con la IF. El 20% creía que influye en su prescripción y el 48% en los demás médicos. El 96% no había recibido información de su colegio profesional, el 80% desconocía si había normas en su sociedad científica y el 50% no sabía si las había en su institución. El 65% consideró necesaria más formación. Los residentes de especialidades hospitalarias presentaron más probabilidad de presentar un ISIF igual o superior al percentil 75 que los de MFyC (odds ratio [OR]: 3,96; intervalo de confianza del 95% [IC95%]: 1,88-8,35). Formarse en entornos informales se asoció a un ISIF menor o igual al percentil 25 (OR: 2,83; IC95%: 1,32-6,07). Conclusiones: Los MIR de la CM tienen un alto nivel de contacto con la IF y creen que su influencia es limitada. Los residentes de especialidades hospitalarias presentan mayor contacto. Las regulaciones son poco conocidas por los residentes, que consideran que es necesaria más formación


Objective: To assess the frequency of exposure and attitudes to the pharmaceutical industry (PI) of residents in the Region of Madrid (RM), Spain, and to analyse the association with specialty, professional environment and training. Methods: Cross-sectional electronic survey in May and June 2015 of all medical residents in RM. We collected sociodemographic variables and those of interaction with the PI in four blocks: frequency of interactions, attitudes and perceptions, environment and regulatory framework, and skills; with the first two blocks we created a Synthetic PI Interaction Index (SPIII). Bivariate and multivariate analysis of logistic regression. Results: 350 resident's responses (28% family and community medicine [FCM], 57% hospital, 15% others). Ninety-eight percent reported interacting with the PI. Twenty percent believed their prescribing was influenced by the PI and 48% believed it was influenced by other doctors. Sixty-five precent considered more training necessary. Ninety-six percent had received no information from their college of physicians, 80% did not know the regulations in their medical society and 50% were unaware of those of their institution. Hospital specialty residents showed more likelihood of SPIII ≥ percentile 75 than those of FCM (odds ratio [OR]: 3.96; 95% confidence interval [95%CI]: 1.88-8.35). Training in informal settings was associated with SPIII ≤ percentile 25 (OR: 2.83; 95%CI: 1.32-6.07). Conclusions: The medical residents in RM had a high level of interaction with the PI and believed its influence low. Hospital specialty residents showed more interaction with the PI. Regulations were not well known by residents and they consideredmore training necessary


Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Industria Farmacéutica/tendencias , Tecnología Farmacéutica/educación , Internado y Residencia/tendencias , Prescripciones de Medicamentos/clasificación , Ética Farmacéutica , Conflicto de Intereses , Relaciones Interinstitucionales , Discusiones Bioéticas
11.
Rev. saúde pública (Online) ; 53: 51, jan. 2019. tab
Artículo en Inglés | LILACS | ID: biblio-1004515

RESUMEN

ABSTRACT OBJECTIVE: Trace the pattern of drug use during delivery hospitalization. METHOD: Cross-sectional study carried out from June to October 2015, included in the 2015 Pelotas births cohort. All women living in the urban area of the city who were hospitalized for delivery were part of the sample. We collected information regarding drug prescription and drug use by mothers during the whole period of hospitalization. Sociodemographic data were obtained in interview after delivery, and other data were obtained from medical charts. The drugs were classified according to the Anatomical Therapeutic Chemical system. RESULTS: All study participants (1,392 women) used at least one drug, with the mean amount being larger the higher the age of the mother, both prepartum/during delivery and postpartum. It was also higher in cases of spinal anesthesia or general anesthesia, cesarean deliveries, school hospitals, and longer hospitalizations. Analysis of the sample as a whole showed no significant difference in the number of drugs used according to hospitalization type, but when stratified by length of hospital stay the mean was higher in SUS hospitalizations than in private and health insurance hospitalizations. Drugs for the nervous system were the most used (30.5%), followed by drugs for the alimentary tract and metabolism (13.8%). The use of anti-infective agents and drugs that act on the cardiovascular and respiratory systems was higher in mothers who underwent cesarean delivery. This study showed high drug consumption in the delivery hospitalization period, and showed cesarean delivery and epidural anesthesia as the main factors related to high drug consumption in this period. CONCLUSIONS: We found high drug consumption in the delivery hospitalization period, and the main factors were cesarean delivery and epidural anesthesia. Drugs that act on the nervous system were the most used.


RESUMO OBJETIVO: Identificar o padrão de uso dos medicamentos durante a internação para o parto. MÉTODO: Estudo transversal realizado de junho a outubro de 2015, inserido na coorte de nascimentos de Pelotas de 2015. Todas as mulheres residentes na zona urbana da cidade que foram internadas para o parto fizeram parte da amostra. Foram coletadas informações referentes à prescrição e uso de medicamentos pela mãe durante todo o período de internação. Dados sociodemográficos foram obtidos na entrevista realizada após o parto, e os demais nos prontuários. Os medicamentos foram classificados de acordo com o sistema Anatomical Therapeutic Chemical. RESULTADOS: Todas as participantes do estudo (1.392 mulheres) utilizaram pelo menos um medicamento, sendo a quantidade média maior quanto maior a idade da mãe, tanto no momento pré/durante o parto como no pós-parto. Também foi maior em casos de raquianestesia ou anestesia geral, partos cesarianos, hospitais escola e internações mais prolongadas. Na análise da amostra como um todo, não houve diferença significativa no número de medicamentos utilizados de acordo com o tipo de hospitalização, mas quando estratificada por período de internação, a média foi maior nas internações pelo SUS que nas internações particulares e por convênios. Medicamentos para o sistema nervoso foram os mais utilizados (30,5%), seguidos dos que atuam no trato alimentar e metabolismo (13,8%). O uso de anti-infecciosos e fármacos que atuam nos sistemas cardiovascular e respiratório foi maior em mães que fizeram cesariana. Este estudo evidenciou elevado consumo de medicamentos no período de internação para o parto, e o parto cesariano e a anestesia peridural como os principais fatores relacionados ao consumo elevado de medicamentos neste período. CONCLUSÕES: Evidenciou-se elevado consumo de medicamentos no período de internação para o parto, sendo os principais fatores a cesariana e a anestesia peridural. Os medicamentos que atuam no sistema nervoso foram os mais utilizados.


Asunto(s)
Humanos , Femenino , Embarazo , Adolescente , Adulto , Adulto Joven , Prescripciones de Medicamentos/estadística & datos numéricos , Cesárea/estadística & datos numéricos , Parto Obstétrico/estadística & datos numéricos , Utilización de Medicamentos/estadística & datos numéricos , Prescripciones de Medicamentos/clasificación , Factores Socioeconómicos , Brasil , Estudios Transversales , Factores de Riesgo , Estudios de Cohortes , Periodo Posparto , Hospitalización , Anestesia Epidural , Anestesia General , Anestesia Raquidea , Persona de Mediana Edad
12.
Swiss Med Wkly ; 148: w14590, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29442341

RESUMEN

BACKGROUND AND OBJECTIVES: Hospitalisation influences drug therapy in ambulatory care and this influence is generally negatively perceived. The few studies that have explored changes in benzodiazepine or sleep medication use as a function of hospitalisation failed to precisely determine the hospital's role in initiating, continuing and discontinuing these drugs on a valid basis. The aim of the study was to ascertain the overall influence of hospitalisation on the prescription of benzodiazepines and Z-drugs in outpatient care with a special focus on the role of different hospital departments and drug classes. METHODS: In a secondary data analysis, we used prescription data for 181 037 patients who visited 127 hospitals and compared the numbers of patients with prescriptions of benzodiazepines and Z-drugs 50 days before and 50 or 100 days after hospitalisation. RESULTS: The proportion of patients who received benzodiazepines or Z-drugs increased from 3.1% before admission to 3.6% at 50 days after discharge and fell to the former level after an additional 50 days. A multivariable logistic regression showed that gender and department had an additional impact on these results. Of those patients without a prescription for a benzodiazepine or Z-drug before admission, 0.6% received a prescription in both time-windows after discharge. Of those patients who were prescribed a benzodiazepine, 38.0% received short-acting substances and 40.3% received long-acting substances before hospitalisation. After hospitalisation, these rates changed to favour short-acting substances (44.4% and 34.4%, respectively). CONCLUSIONS: The hospital effect on initiating and increasing hypnotic or sedative drug use seems to be only moderate and temporary. A change in favour of short-acting substances is even welcome. In less than 1% of patients, the hospital initiated the continuous use of benzodiazepines and Z-drugs, which may put pressure on primary care physicians. However, the widespread use of these drugs in hospitals does not seem to be continued on a large scale in primary care.


Asunto(s)
Benzodiazepinas/uso terapéutico , Prescripciones de Medicamentos , Hospitalización/estadística & datos numéricos , Hipnóticos y Sedantes/uso terapéutico , Benzodiazepinas/efectos adversos , Prescripciones de Medicamentos/clasificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Alta del Paciente , Atención Primaria de Salud , Factores Sexuales , Factores de Tiempo
13.
Med J Aust ; 208(1): 18-23, 2018 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-29320668

RESUMEN

OBJECTIVE: To determine the use of different anticoagulation therapies in rural Western Australia; to establish whether remoteness from health care services affects the choice of anticoagulation therapy; to gather preliminary data on anticoagulation therapy safety and efficacy. DESIGN: Retrospective cohort study of patients hospitalised with a principal diagnosis of atrial fibrillation/flutter (AF) or venous thromboembolism (VTE) during 2014-2015. SETTING: Four hospitals serving two-thirds of the rural population of Western Australia. PARTICIPANTS: 609 patients with an indication for anticoagulation therapy recorded in their hospital discharge summary for index admission. MAIN OUTCOME MEASURES: Prescribing rates of anticoagulation therapies by indication for anticoagulation and distance of patient residence from their hospital. The primary safety outcome was re-hospitalisation with a major or clinically relevant non-major bleeding event; the primary lack-of-efficacy outcome was re-hospitalisation for a thromboembolic event. RESULTS: The overall rates of prescription of NOACs and warfarin were similar (34% v 33%). A NOAC was prescribed more often than warfarin for patients with AF (56.0% v 42.2% of those who received an anticoagulant; P < 0.001), but less often for patients with VTE (29% v 48%; P < 0.001). Warfarin was prescribed for 38% of patients who lived locally, a NOAC for 31% (P = 0.013); for non-local patients, the respective proportions were 29% and 36% (P = 0.08). 69% of patients with AF and a CHA2DS2-VASc score ≥ 1 were prescribed anticoagulation therapy. Patients treated with NOACs had fewer bleeding events than patients treated with warfarin (nine events [4%] v 20 events [10%]; P = 0.027). CONCLUSIONS: In rural WA, about one-third of patients with an indication for anticoagulation therapy receive NOACs, but one-third of patients with AF and at risk of stroke received no anticoagulant therapy, and may benefit from NOAC therapy.


Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Prescripciones de Medicamentos/clasificación , Tromboembolia Venosa/tratamiento farmacológico , Administración Oral , Anciano , Anciano de 80 o más Años , Australia , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Población Rural , Terapia Trombolítica , Resultado del Tratamiento , Warfarina
14.
Pharm. pract. (Granada, Internet) ; 15(3): 0-0, jul.-sept. 2017. tab, graf
Artículo en Inglés | IBECS | ID: ibc-165684

RESUMEN

Objective: 1) To evaluate the relationship between physician-pharmacist agreement about the off-label drug use and 2) and to identify the most common off-label medication category/indications and prescriber clinical disciplines in private settings in Baghdad area, Iraq Methods: This study evaluated 980 off-label use requests in the private clinical settings within Baghdad area, Iraq from October 2013 to September 2015. The efficacy, safety, and convenience of each drug request and its alternative options were evaluated according to the patient health and demographic characteristics and standard guidelines. Results: Of the 980 physician off-label requests, only 22.7% were approved by the pharmacists. Rheumatology and Nephrology accounted for the highest ratio of off-label use requests for adults (30.3% and 26.3%). The pharmacist rejection ratio of off-label use was comparable between the two groups (p>0.05). Most of the issued requests were attributed either to unapproved indication or to combination of more than one drug (38% and 35.3%). A low acceptance rate was reported in the requests issued for treatment in different clinical lines to the authorized one (11.9%). The lowest rate of acceptance was reported in the requests that had very low evidence level (9.1%). The mostly prescribed medications were musculoskeletal agents (28.9%). Finally, 78.2% of the requests came from clinical branches for adults. Although the agreement rate for requests in adults was higher than that in pediatrics, the two rates were not significantly different. Conclusion: Community pharmacists should effectively take responsibility for assessing off-label drug requests in Iraqi private settings. The quality of evidence does not represent the major factor influencing the approval rate of off-label drug use. The availability of safer and/or affordable alternatives and prescribing for a different patient age category highly impacted the pharmacists’ approval rate (AU)


No disponible


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Relaciones Interprofesionales , Farmacéuticos , Uso Fuera de lo Indicado/normas , Actitud del Personal de Salud , Práctica Privada , Prescripciones de Medicamentos/clasificación , Estudios Prospectivos , Irak/epidemiología , Servicios Comunitarios de Farmacia/organización & administración , Servicios Comunitarios de Farmacia/normas
15.
Rev Med Chil ; 145(1): 33-40, 2017 Jan.
Artículo en Español | MEDLINE | ID: mdl-28393967

RESUMEN

BACKGROUND: Adverse effects of medications are an important cause of morbidity and hospital admissions. Errors in prescription or preparation of medications by pharmacy personnel are a factor that may influence these occurrence of the adverse effects Aim: To assess the frequency and type of errors in prescriptions and in their preparation at the pharmacy unit of a regional public hospital. MATERIAL AND METHODS: Prescriptions received by ambulatory patients and those being discharged from the hospital, were reviewed using a 12-item checklist. The preparation of such prescriptions at the pharmacy unit was also reviewed using a seven item checklist. RESULTS: Seventy two percent of prescriptions had at least one error. The most common mistake was the impossibility of determining the concentration of the prescribed drug. Prescriptions for patients being discharged from the hospital had the higher number of errors. When a prescription had more than two drugs, the risk of error increased 2.4 times. Twenty four percent of prescription preparations had at least one error. The most common mistake was the labeling of drugs with incomplete medical indications. When a preparation included more than three drugs, the risk of preparation error increased 1.8 times. CONCLUSIONS: Prescription and preparation of medication delivered to patients had frequent errors. The most important risk factor for errors was the number of drugs prescribed.


Asunto(s)
Composición de Medicamentos , Prescripciones de Medicamentos/estadística & datos numéricos , Prescripción Inadecuada/efectos adversos , Prescripción Inadecuada/estadística & datos numéricos , Errores de Medicación/efectos adversos , Errores de Medicación/estadística & datos numéricos , Medicamentos bajo Prescripción/efectos adversos , Estudios Transversales , Prescripciones de Medicamentos/clasificación , Hospitales , Humanos , Prescripción Inadecuada/clasificación , Errores de Medicación/clasificación , Pacientes Ambulatorios , Sector Público
16.
Rev. méd. Chile ; 145(1): 33-40, ene. 2017. tab
Artículo en Español | LILACS | ID: biblio-845501

RESUMEN

Background: Adverse effects of medications are an important cause of morbidity and hospital admissions. Errors in prescription or preparation of medications by pharmacy personnel are a factor that may influence these occurrence of the adverse effects Aim: To assess the frequency and type of errors in prescriptions and in their preparation at the pharmacy unit of a regional public hospital. Material and Methods: Prescriptions received by ambulatory patients and those being discharged from the hospital, were reviewed using a 12-item checklist. The preparation of such prescriptions at the pharmacy unit was also reviewed using a seven item checklist. Results: Seventy two percent of prescriptions had at least one error. The most common mistake was the impossibility of determining the concentration of the prescribed drug. Prescriptions for patients being discharged from the hospital had the higher number of errors. When a prescription had more than two drugs, the risk of error increased 2.4 times. Twenty four percent of prescription preparations had at least one error. The most common mistake was the labeling of drugs with incomplete medical indications. When a preparation included more than three drugs, the risk of preparation error increased 1.8 times. Conclusions: Prescription and preparation of medication delivered to patients had frequent errors. The most important risk factor for errors was the number of drugs prescribed.


Asunto(s)
Humanos , Prescripciones de Medicamentos/estadística & datos numéricos , Composición de Medicamentos , Medicamentos bajo Prescripción/efectos adversos , Prescripción Inadecuada/efectos adversos , Prescripción Inadecuada/estadística & datos numéricos , Errores de Medicación/efectos adversos , Errores de Medicación/estadística & datos numéricos , Pacientes Ambulatorios , Prescripciones de Medicamentos/clasificación , Estudios Transversales , Sector Público , Prescripción Inadecuada/clasificación , Hospitales , Errores de Medicación/clasificación
17.
Health Econ ; 26(6): 743-752, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27174417

RESUMEN

New products usually offer advantages over existing products, but in health care, most new drugs are 'me-too', comparable in effectiveness and side effects to existing drugs, but with a more ambiguous evidence base around adverse effects. Despite this, new treatments drive increased health care spending, suggesting a preference for 'newness' in this setting. We explore (1) whether preferences for treatments labeled 'new' exist and (2) persist once the ambiguity in the evidence base reflecting newness is described. We use a Canadian general population sample (n = 2837) characterized by their innovativeness in adopting new products in normal markets. We found that innovators/early adopters (n = 173) had significant preferences for 'newer' treatments (B = 0.162, p = 0.038) irrespective of comparable benefits and side effects and all respondents had significant preferences for less ambiguity in benefit/side effect estimates. Notably, when 'newness' was combined with ambiguity, no significant preferences for new treatments were observed regardless of respondent innovativeness. We conclude that preferences for new products exist for some people in health care markets but disappear when the implication of ambiguity in the evidence base for new treatments is communicated. Physicians should avoid describing treatments as 'new' or be mindful to qualify the implications of 'new' treatments in terms of evidence ambiguity. Copyright © 2016 John Wiley & Sons, Ltd.


Asunto(s)
Conducta de Elección , Prescripciones de Medicamentos/clasificación , Mercadotecnía/métodos , Incertidumbre , Adulto , Canadá , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Humanos , Masculino , Prioridad del Paciente
18.
Ann Pharmacother ; 50(7): 534-40, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27147704

RESUMEN

BACKGROUND: Medication reconciliation to identify discrepancies is a National Patient Safety Goal. Increasing medication number and complex medication regimens are associated with discrepancies, nonadherence, and adverse events. The Medication Regimen Complexity Index (MRCI) integrates information about dosage form, dosing frequency, and additional directions. OBJECTIVE: This study evaluates the association of MRCI scores and medication number with medication discrepancies and commissions, a discrepancy subtype. METHODS: This was a retrospective cohort study of a convenience sample of 104 ambulatory care patients seen from April 2010 to July 2011 within the Department of Veterans Affairs. Primary outcomes included any medication discrepancy and commissions. Primary exposures included MRCI scores and medication number. Multivariable logistic regression models associated MRCI scores and medication number with discrepancies. Receiver operating characteristic (ROC) curves provided discrepancy thresholds. RESULTS: For the 104 patients analyzed, the median MRCI score was 25 (interquartile range [IQR] = 14-43), and the median medication number was 8 (IQR = 5-13); 60% of patients had any discrepancy, whereas 36% had a commission. In adjusted analyses, patients with MRCI scores ≥25 or medication number ≥8 were more likely to have commissions (odds ratio [OR] = 3.64, 95% CI = 1.41-9.41; OR = 4.51, 95% CI = 1.73-11.73, respectively). The unadjusted ROC threshold for commissions was 36 for MRCI (sensitivity, 59%; specificity, 82%) and 9 for medication number (sensitivity 68%; specificity 67%). CONCLUSION: Patients with either MRCI scores ≥25 or ≥8 medications were more likely to have commissions. Given equal performance in predicting discrepancies, the efficiency and simplicity of medication number supports its use in identifying patients for intensive medication review beyond medication reconciliation.


Asunto(s)
Atención Ambulatoria/estadística & datos numéricos , Prescripciones de Medicamentos/estadística & datos numéricos , Revisión de la Utilización de Medicamentos/métodos , Conciliación de Medicamentos/estadística & datos numéricos , Polifarmacia , Anciano , Atención Ambulatoria/métodos , Protocolos Clínicos , Prescripciones de Medicamentos/clasificación , Prescripciones de Medicamentos/normas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Evaluación del Resultado de la Atención al Paciente , Estudios Retrospectivos , Estados Unidos , United States Department of Veterans Affairs , Veteranos
20.
Int J Cardiol ; 215: 248-51, 2016 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-27128540

RESUMEN

BACKGROUND: Limited data are available to assess whether access to and quality of cardiovascular disease (CVD) care are comparable among men and women in India. We analyzed data from the American College of Cardiology's PINNACLE (Practice Innovation and Clinical Excellence) India Quality Improvement Program (PIQIP) to evaluate gender disparities in CVD care delivery. METHODS AND RESULTS: Between 2011 and 2015, we collected data on performance measures for patients with coronary artery disease (CAD) (n=14,010), heart failure (HF) (n=11,965) and atrial fibrillation (AF) (n=496) in PIQIP, among 17 participating practices. The total number of women was 31,796 (32.0%). Women had fewer total encounters compared to men during the study interval (mean number of encounters=2.59 vs. 2.82 for women and men, respectively, p≤0.001). Women were significantly younger (48.9years vs. 51.5years, p≤0.01), but had a higher co-morbidity burden compared to men - hypertension (62.0% vs. 45.6%, p≤0.01), diabetes (39.4% vs. 35%, p≤0.01), and hyperlipidemia (3.7% vs. 3.1%, p=0.19). On the contrary, the guideline-directed medication prescriptions were strikingly lower in women with CAD compared to men - aspirin (38% vs. 50.4%, p≤0.001), aspirin or thienopyridine combination (46.9% vs. 57.2%, p≤0.001), and beta-blockers (36.8% vs. 47.8%, p≤0.001). Similarly, among women with ejection fraction ≤40%, the use of guideline-directed medical therapy was significantly lower compared to men for beta-blockers (30.8% vs. 37.0%, p≤0.001), angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) (29.3% vs. 34.9%, p≤0.001), and beta-blockers/ACE-i or ARBs (24.6% vs. 31.0%, p≤0.001). Among patients with atrial fibrillation and CHADS2 score≥2, more women were on oral anticoagulation (19.6% vs. 14.6%, p=0.34), although this was not significantly different, and the overall number of patients with atrial fibrillation was low. CONCLUSIONS: Despite a significantly higher co-morbidity burden in women, we found fewer women receiving guideline-directed medical therapy for CVD compared with men. If such disparities are confirmed in the larger Indian population, it is important to find potential causes for, and seek solutions to narrow this gap.


Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Prescripciones de Medicamentos/estadística & datos numéricos , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Insuficiencia Cardíaca/tratamiento farmacológico , Factores de Edad , Comorbilidad , Prescripciones de Medicamentos/clasificación , Medicina Basada en la Evidencia , Femenino , Humanos , India , Masculino , Guías de Práctica Clínica como Asunto , Mejoramiento de la Calidad , Indicadores de Calidad de la Atención de Salud , Sexismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...